In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?

The interim analysis of the AMPLIFY trial, published in the New England Journal of Medicine, presents strong evidence that could influence clinical practice for treatment-naïve chronic lymphocytic leukemia (CLL) patients without del(17p) or TP53 mutations. The AMPLIFY trial is the first phase 3 stud...

Yes, these data have already changed my practice. For many patients, an all-oral fixed-duration doublet is preferable to venetoclax/obinutuzumab. From the AMPLIFY trial, I am comfortable giving acalabrutinib/venetoclax to patients with IGHV-mutated CLL. For those with unmutated IGHV who desire fixed...